Chandan Devireddy, MD, ACTSI investigator and Assistant Professor of Medicine in the Division of Cardiology. He is currently involved in research focusing on novel interventional technology in autonomic modulation for resistant hypertension and potentially other systemic diseases, transcatheter valve intervention for the treatment of structural heart disease, and improving outcomes in complex coronary and peripheral vascular disease. He is the site principal investigator of a trial funded by Medtronic Vascular, Inc. entitled, “Global clinical study of renal denervation with the Symplicity Spyral™: multi-electrode renal denervation system in patients with uncontrolled hypertension in the absence of antihypertensive medications.” Outside of work, he and his wife enjoy watching the world come to life through the eyes of their two sons. Rare free time is spent watching Wolverine football, TV series, cooking, and biking the new Beltline trail.
Emory News Center | Florida man receives the gift of life, thanks to U.S. Customs officer and Emory cardiology teams
December 31, 2015
Atlanta Journal-Constitution |WSB-TV | WAGA-TV | Customs agent saves dying man at Atlanta airport
December 30, 2015
Washington Post | Do cellphones belong in the operating room?
July 14, 2015
CNN | Why you should act quickly at first sign of heart attack
December 18, 2012
Devireddy CM and Bates MC. “Experience With an Innovative New Food and Drug Administration Pathway for First-in-Human Studies: Carotid Baroreceptor Amplification for Resistant Hypertension.” JACC Cardiovasc Interv. 2014 Oct 7. pii: S1936-8798(14)01243-6. [Epub ahead of print] Read more…
“Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.” Eur Heart J. 2014 Nov 16. pii: ehu441. [Epub ahead of print] Read more…
“Prevalence of Resistant Hypertension and Eligibility for Catheter-Based Renal Denervation in Hypertensive Outpatients.” Am J Hypertens 2013 Dec;26(12):1452-8. Read more…